As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
10 Analysts have issued a Affimed N.V. forecast:
10 Analysts have issued a Affimed N.V. forecast:
| Sep '24 |
+/-
%
|
||
| Revenue | 1.01 1.01 |
95%
95%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -77 -77 |
41%
41%
|
|
| EBIT (Operating Income) EBIT | -81 -81 |
39%
39%
|
|
| Net Profit | -81 -81 |
41%
41%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
| Head office | Netherlands |
| CEO | Shawn Leland |
| Employees | 76 |
| Founded | 2000 |
| Website | www.affimed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


